Skip to content Skip to footer
Subscribe Now

NEWS

InduPro Therapeutics Collaborates with Eli Lilly in ~$950M Oncology Therapeutic Discovery Deal
Shots: InduPro has entered into a global strategic collaboration & licensing agreement with Eli Lilly to discover novel oncology treatments using InduPro’s proximity-guided platform Lilly will gain access to InduPro’s AI/ML-enabled MInt platform, with InduPro leading early discovery to identify co-target pairs & advance bispecific & multispecific antibody programs from the collaboration As per the…
3 days ago
Eli Lilly to Acquire Ventyx for ~$1.2B
Shots: Eli Lilly has entered into a definitive agreement to acquire Ventyx, strengthening Lilly’s capabilities in inflammatory-mediated diseases As per the deal, Eli Lilly will acquire Ventyx for $14/share in an all-cash transaction, representing an aggregate equity value of ~$1.2B; closing is expected in H1’26 Ventyx is advancing a pipeline of oral small-molecule therapies, incl.…
3 days ago
Fresenius Kabi
Fresenius Kabi Launches an Additional Presentation of Otulfi (Biosimilar, Stelara)
Shots: Fresenius Kabi has launched Otulfi, an interchangeable biosimilar version of Stelara (ustekinumab), in a 45 mg/0.5 mL single-dose vial presentation for SC injection FDA approval was granted in Sep 2024 on the basis of analytical, pre-clinical, clinical & manufacturing data, showing similar efficacy, safety, PK & immunogenicity of Otulfi vs Stelara among mod. to sev.…
3 days ago
Cartography Biosciences and Pfizer Forge ~$865M Deal for Discovery of Tumor-Selective Antigens
Shots: Cartography has entered into a strategic collaboration with Pfizer to discover tumor-selective antigens, leveraging Cartography’s ATLAS & SUMMIT platforms Under a multi-year deal, Cartography will discover & validate tumor-selective antigens in an undisclosed cancer, with Pfizer holding opt-in rights for research, development & commercialization; Cartography retains full ownership of its lead asset CBI-1214 Cartography…
3 days ago
Amgen Acquires Dark Blue Therapeutics for ~$840M
Shots: Amgen has acquired Dark Blue Therapeutics, strengthening its early oncology discovery efforts & pipeline As per the deal, Amgen acquired Dark Blue Therapeutics in a transaction valued at ~$840M, integrating Dark Blue into its existing research organization Acquisition will add a preclinical small molecule that degrades MLLT1/3 in select acute myeloid leukemia subtypes, showing differentiated anti-cancer activity…
4 days ago
GSK New
GSK Reports the MHLW Approval of Exdensur (Depemokimab) for Severe Asthma and CRSwNP
Shots: GSK’s Exdensur was approved for sev. or refractory bronchial asthma unresponsive to existing therapies & for CRSwNP in pts whose disease remains inadequately controlled with SoC, based on the P-III (SWIFT & ANCHOR) trials, respectively; filings under regulatory review in the EU & China SWIFT-1 (n=382) & SWIFT-2 (n=380) trials showed depemokimab reduced asthma…
4 days ago
Acesion Pharma Initiates P-II Trial of AP31969 to Treat Atrial Fibrillation
Shots: Acesion Pharma has enrolled the first patients in the P-II trial assessing AP31969 in pts with atrial fibrillation, with completion anticipated by Q1’27 Trial will enrol 200 pts across eight EU countries, with AF burden as the 1EP. Safety will be monitored using implantable loop recorders for continuous 24/7 cardiac rhythm tracking In 2025,…
4 days ago
Load more